Clinical study
dermatologytimes.com
Wearable Electrotrichogenic Device Shows Significant Hair Density Gains in Men with AGA
A randomized, double-blind, sham-controlled trial published inDermatology and Therapysuggests that niostem’s electrotrichogenic (ETG) wearable device may offer a novel non pharmacologic option for men with androgenetic alopecia (AGA). In the 24-week study, 81 male patients with Norwood-Hamilton II-VI AGA used either the active device or a sham comparator for 30 minutes daily, with efficacy assessed in participants achieving at least 70% adherence.Dermatology Timesspoke to niostem’s co-founder and chief technology officer, Carlos Chacón, PhD, about the recently published research.
